Hebei Changshan Biochemical Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hebei Changshan Biochemical Pharmaceutical has a total shareholder equity of CN¥1.8B and total debt of CN¥1.6B, which brings its debt-to-equity ratio to 92.6%. Its total assets and total liabilities are CN¥4.7B and CN¥2.9B respectively.
Key information
92.6%
Debt to equity ratio
CN¥1.64b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥314.22m |
| Equity | CN¥1.77b |
| Total liabilities | CN¥2.91b |
| Total assets | CN¥4.69b |
Recent financial health updates
Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
Jan 05
Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Recent updates
Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
Jan 05Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Oct 30Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%
Oct 08Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01Financial Position Analysis
Short Term Liabilities: 300255's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥2.0B).
Long Term Liabilities: 300255's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥939.9M).
Debt to Equity History and Analysis
Debt Level: 300255's net debt to equity ratio (74.9%) is considered high.
Reducing Debt: 300255's debt to equity ratio has increased from 38.7% to 92.6% over the past 5 years.
Debt Coverage: 300255's debt is not well covered by operating cash flow (18.7%).
Interest Coverage: Insufficient data to determine if 300255's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 02:31 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Qiang | China International Capital Corporation Limited |
| Xiaoyan Wang | China Minzu Securities |
| Hai Zhu Peng | Huatai Research |